Gastroblastoma is a rare distinctive biphasic tumor of the stomach. The molecular biology of gastroblastoma has not been studied, and no affirmative diagnostic markers have been developed. We retrieved two gastroblastomas from the consultation practices of the authors and performed transcriptome sequencing on formalin-fixed paraffin-embedded tissue. Recurrent predicted fusion genes were validated at genomic and RNA levels. The presence of the fusion gene was confirmed on two additional paraffin-embedded cases of gastroblastoma. Control cases of histologic mimics (biphasic synovial sarcoma, leiomyoma, leiomyosarcoma, desmoid-type fibromatosis, EWSR1-FLI1-positive Ewing sarcoma, Wilms' tumor, gastrointestinal stromal tumor, plexiform fibromyxoma, Sonic hedgehog-type medulloblastomas, and normal gastric mucosa and muscularis propria were also analyzed. The gastroblastomas affected two males and two females aged 9-56 years. Transcriptome sequencing identified recurrent somatic MALAT1-GLI1 fusion genes, which were predicted to retain the key domains of GLI1. The MALAT1-GLI1 fusion gene was validated by break-apart and dual-fusion FISH and RT-PCR. The additional two gastroblastomas were also positive for the MALAT1-GLI1 fusion gene. None of the other control cases harbored MALAT1-GLI1. Overexpression of GLI1 in the cases of gastroblastomas was confirmed at RNA and protein levels. Pathway analysis revealed activation of the Sonic hedgehog pathway in gastroblastoma and gene expression profiling showed that gastroblastomas grouped together and were most similar to Sonic hedgehog-type medulloblastomas. In summary, we have identified an oncogenic MALAT1-GLI1 fusion gene in all cases of gastroblastoma that may serve as a diagnostic biomarker. The fusion gene is predicted to encode a protein that includes the zinc finger domains of GLI1 and results in overexpression of GLI1 protein and activation of the Sonic hedgehog pathway.
Gastroblastoma is an extremely rare, distinctive, biphasic tumor of the stomach. To date, only eight cases have been reported, all in patients under 30 years of age. [1] [2] [3] [4] [5] [6] Owing to its biphasic morphology, gastroblastoma may mimic other biphasic tumors of the stomach (eg, synovial sarcoma and sarcomatoid carcinoma). In smaller biopsies that do not demonstrate biphasic morphology, the differential diagnosis of gastroblastoma is broad, and includes a wide variety of other gastric tumors characterized by relatively bland epithelioid or spindled cells, including the recently described plexiform fibromyxoma, a rare gastric spindle cell neoplasm recently shown to harbor a MALAT1-GLI1 fusion gene in~15-20% of cases. 7 The molecular pathogenesis of gastroblastoma is unknown, and there are currently no ancillary tests that are known to be useful in its differential diagnosis with other gastric neoplasms.
We hypothesized that the distinctive clinical and morphological features of gastroblastoma suggested a translocation-associated neoplasm, and for this reason we studied the morphological, immunohistochemical, and molecular genetic features of a series of these rare tumors.
Materials and methods

Cases
All available routinely stained slides, immunohistochemical studies, and formalin-fixed paraffinembedded tissue blocks from four cases of gastroblastoma were retrieved from our collective consultation files and re-reviewed by two of the authors (RPG and ALF). The clinicopathological features of two of these cases have been previously published (case nos. 1 and 3). 2, 3 Clinical information including patient age, sex, tumor size, metastases, and clinical follow-up was obtained whenever possible.
Formalin-fixed paraffin-embedded tissue blocks from cases of potential histologic mimics (controls) were also selected. The controls included the following: biphasic synovial sarcoma (n = 7); leiomyoma (n = 5); leiomyosarcoma (n = 5); desmoid-type fibromatosis (n = 5); EWSR1-FLI1-positive Ewing sarcoma (n = 5); Wilms' tumor (n = 2); plexiform fibromyxoma (n = 2); gastrointestinal stromal tumor (n = 2); and normal gastric muscularis propria (n = 1).
RNA Sequencing
Global transcriptome sequencing was performed on formalin-fixed paraffin-embedded tissue from two gastroblastomas (case nos. 1 and 2) and one sample of randomly selected normal gastric muscularis propria. Total RNA libraries were prepared from each case (Illumina TruSeq RNA Access) and run on the Illumina High Seq-2000 for 101 bp paired-end reads. Gene expression counts were obtained using the MAP-RSeq v.2.0.0 workflow. MAP-RSeq consists of alignment with TopHat 2.0.12 against the human hg19 genome build and gene counts with the Subread package 1.4.4. Gene annotation files were obtained from Ensemble version 75. Gene counts were normalized using the reads per kilobase per million mapped reads approach. Differential expression analysis was performed using edgeR 2.6.2. Gene fusions were identified using TopHat-Fusion 8 and RNA sequencing (RNASeq) quality was assessed with Fusion Sense. 9 
Pathway Analysis
Enriched canonical pathways for differentially expressed genes obtained from the RNASeq data were investigated using the Ingenuity pathway analysis software IPA (Ingenuity Systems, www. ingenuity.com). Canonical pathways, biological functions, and networks were used for critical investigation of cancer-related pathways.
Reverse Transcriptase-PCR and Fluorescence In Situ Hybridization
Reverse transcriptase-PCR (RT-PCR) and fluorescence in situ hybridization (FISH) were used to validate recurrent predicted fusion genes from RNASeq analysis at transcriptional and genomic levels, respectively, in all four cases. RT-PCR was performed on case nos. 1 and 2 as follows: 500 ng of RNA from formalin-fixed paraffin-embedded tissue was converted into cDNA in a 20 μl of reaction volume using the iScript Select cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). The MALAT1-GLI1 fusion genes (Genbank accession no.: MALAT1: NR_002819.3; GLI1: NM_005269.2) were validated using multispecific PCR primers. For case no. 1, the following primer sequences were utilized: 5′-AGGTTACTAAGATATTGCTTAGCGT-3′ (forward) and 5′-CAGACTTCAGCTTCCCCAGG-3′ (reverse). For case no. 2, primer sequences 5′-GGTT ACTAAGATATTGCTTAGCGTT-3′ (forward) and 5′-CCTGAGCTGAGGGAAATCAGG-3′ (reverse) were utilized. The housekeeping gene phosphoglycerokinase (PGK1; NM_000291.3) was amplified along with MALAT1-GLI1 fusion transcripts to check for the RNA quality, using a primer set 5′-CAGTTTGGAGCT CCTGGAAG-3′ (forward) and 5′-CTGGCACTGCATCT CTTGGCC-3′ (reverse). PCR was carried out in a 25 μl final reaction volume containing 2 μl of cDNA template using the conditions previously reported by our group. 10 After amplification, the PCR products were visualized by 3% agarose gel electrophoresis. No reverse transcriptase in RT reaction was used as negative control. All positive RT-PCR products were confirmed by Sanger sequencing.
FISH was done for the rearrangement of the MALAT1 locus, the GLI1 locus, and the fusion of MALAT1-GLI1 using lab-developed protocols at the Mayo Clinic. MALAT1 break-apart (BAP) and MALAT1-GLI1 dual-fusion FISH (D-FISH) were done on all four gastroblastomas and both plexiform fibromyxomas. GLI1 BAP FISH was done on all four gastroblastomas and all controls.
For MALAT1 BAP FISH, human bacterial artificial chromosomes (BACs) flanking the MALAT1 locus were identified using the University of California Santa Cruz February 2009 Assembly hg19. The 5′-MALAT1 clones (RP11-399J13, RP11-251P4, and RP11-436C17) were labeled by nick translation with Spectrum Green dUTP (Abbott Molecular/Vysis Products, IL) and the 3′-MALAT1 clones (RP11-472D14 and RP11-263H6) were labeled with Spectrum Orange dUTP (Abbott Molecular/Vysis Products). Labeled clones were combined to create a dual-color BAP probe set.
For GLI1 BAP FISH, human BACs flanking the GLI1 locus were identified in a similar manner to the above. The 5′-GLI1 clones (RP11-57K19, RP11-756H6, and WI2-684I4) were labeled as above with Spectrum Orange dUTP (Abbott Molecular/Vysis Products) and the 3′-GLI1 clones (WI2-2018I10, WI2-1865J18, and RP11-571M6) were labeled with Spectrum Green dUTP (Abbott Molecular/Vysis Products). Labeled clones were combined to create a dual-color BAP probe set.
For MALAT1-GLI1 D-FISH, human BACs spanning both the MALAT1 and GLI1 loci were identified similar to the above. The MALAT1 clones (RP11-1104L6 and RP11-472D15) were labeled by with Spectrum Orange dUTP (Abbott Molecular/ Vysis Products) and the GLI1 clones (RP11-57K19, RP11-258J5, and RP11-181L23) were labeled with Spectrum Green dUTP (Abbott Molecular/Vysis Products). Labeled clones were combined to create a D-FISH probe set.
Each probe set (MALAT1 BAP, GLI1 BAP, and MALAT1-GLI1 D-FISH) was applied to individual 5 μm formalin-fixed paraffin-embedded unstained slides, hybridized, and washed according to a previously published FISH protocol. 11 
Gene Expression Profiling
Gene expression profiling was performed on RNA derived from formalin-fixed paraffin-embedded tissue of case nos. 1 and 2 of gastroblastoma along with six leiomyomata, three desmoid-type fibromatosis, three Sonic hedgehog-type medulloblastomas, two biphasic synovial sarcomas, two Wilms' tumors, and two plexiform fibromyxomas as controls. Transcriptome profiles were measured using Affymetrix Human Transcriptome Array 2.0 (http://www.affy metrix.com). Gene-level normalization and signal summarization were done using the Affymetrix Expression Console (Affymetrix). To study the proximity of tumors on the basis of their expression profiles, probes with the highest variance across all tumors were first selected. Next, unsupervised hierarchical clustering was performed on the normalized data using heatmap.2 using euclidean distance and ward.D2 linkage metrics.
Immunohistochemistry
GLI1 immunohistochemistry was performed on 5 μm unstained sections of four cases of gastroblastoma, two examples of Sonic Hedgehog-type medulloblastoma, and the following controls: seven biphasic synovial sarcomas; five desmoid-type fibromatosis; five leiomyomas; five leiomyosarcomas; five Ewing sarcomas, two Wilms' tumors, and two plexiform fibromyxomas using clone C-1 (Santa Cruz Biotechnology, Dallas, TX, USA), dilution 1:50 and EDTA antigen retrieval for 20 min. Antibody incubation and detection for GLI1 were done on the Leica BOND RX staining platform (pre-treatment BOND ER 2) with detection using a Leica BOND Refine Polymer Detection System, DS9800 (Leica Biosystems). Normal cerebellum and normal liver were used as positive and negative controls, respectively. Table 1 summarizes the clinicopathological features of the cases in this study. The gastroblastomas arose in two males and two females aged 9-56 years (mean 30 ± 19 years). The tumors were centered in the stomach with three cases involving the antrum. In two patients, metastases were present at the time of consultation. The metastases involved a perigastric lymph node, peritoneum, liver, and urinary bladder in one case (case no. 1) and the liver in the other case (case no. 4). Three cases were resection specimens and the fourth (case no. 4) was a needle biopsy from the stomach.
Results
Clinical Features
Histologic and Immunohistochemical Features
Histologically, all tumors displayed biphasic morphology. Two cases showed relatively even proportions of epithelial and spindled elements, whereas the other two cases were composed largely of epithelial cells. The epithelial elements of all tumors were composed of nests of uniform epithelioid cells with scant amounts of pale eosinophilic cytoplasm and round to oval, normochromic nuclei. Within these tumor nests, rosette-like structures with central eosinophilic material were frequently present. The spindle cell component was characterized by bland, elongated, slender cells separated by a loose myxoid matrix, creating a reticular appearance. Mitotic figures were occasionally seen and were normal in appearance (Figure 1a-f) . Histologic sections from a lymph node metastasis were available for case no. 1, and showed features similar to the primary tumor (Figure 1b) . The metastatic lesions for case no. 4 were radiographically noted, but not biopsied. Table 2 summarizes the immunohistochemical results. The epithelial component was positive for pan-keratins AE1/AE3 or OSCAR in all cases and was consistently negative for chromogranin and synaptophysin. The spindle component was positive for vimentin in both cases where this marker was used. One case showed patchy smooth muscle actin expression but smooth muscle actin was negative in two other cases.
RNA Sequencing
RNA sequencing (RNASeq) followed by fusion gene analysis identified a recurrent, fusion of MALAT1 Table 1 ).
Reverse Transcriptase-PCR
RT-PCR confirmed the presence of the MALAT1-GLI1 fusion transcript in both case nos. 1 and 2 of gastroblastoma (Figure 2a ). The lymph node metastasis from case no. 1 was also positive for the MALAT1-GLI fusion transcript. Sanger sequencing of the cDNA from case nos. 1 and 2 confirmed fusion of MALAT1 to GLI1 (Figure 2b ). RT-PCR failed for cases 3 and 4, owing to nucleic acid degradation as evidenced by lack of amplification of the internal control PGK.
Fluorescence In Situ Hybridization MALAT1 BAP, GLI1 BAP, and MALAT1-GLI1 D-FISH were positive for rearrangement of the MALAT1 and GLI1 loci and fusion of the MALAT1 and GLI1 loci, respectively, in all four studied cases (Figure 3a and b) in both the epithelial and spindle cell components.
RT-PCR and FISH Results in Morphological Mimics
Potential histologic mimics, including seven biphasic synovial sarcomas, two gastrointestinal stromal tumors, five leiomyomas, five leiomyosarcomas, five desmoid-type fibromatoses, five Ewing sarcomas, two Wilms' tumors, and two plexiform fibromyxomas were also studied by RT-PCR and FISH. One plexiform fibromyxoma was positive for MALAT1 rearrangement but negative for GLI1 rearrangement and MALAT1-GLI1 D-FISH (data not shown). The other plexiform fibromyxoma was negative for each of the FISH strategies. All of the other controls were negative for MALAT1-GLI1 by RT-PCR and were negative for GLI1 BAP FISH.
RNASeq Analysis
By RNASeq analysis of case nos. 1 and 2, GLI1 and its known target genes PTCH1, SOX2, VEGFA, and CCND1 were differentially overexpressed in gastroblastoma with a greater than eightfold change (P o 0.004 for each) compared to normal gastric muscularis propria (Supplementary Table 2 ). This indicates that the MALAT1-GLI1 fusion transcript results in the expression of GLI1. Pathway analysis on these cases looking at differentially expressed genes showing a greater than threefold change and a false discovery rate o 0.05 from this data set identified upregulation of the Sonic hedgehog pathway (including GLI1, HHIP, PTCH1, and PTCH2) in the tumor cells of gastroblastoma (P = 0.013) and downregulation of the protein kinase A pathway, an antagonist of Sonic hedgehog pathway signaling (P = 4.57 × 10 − 8 ).
GLI1 Immunohistochemistry
We confirmed GLI1 overexpression by immunohistochemistry, showing that GLI1 was strongly and diffusely positive in a nuclear and cytoplasmic pattern in three of three cases of gastroblastoma ( Figure 4) . Because of our finding of upregulation of the Sonic Hedgehog pathway in gastroblastoma (above), we also studied two cases of Sonic Hedgehog-type medulloblastomas, both of which were also diffusely positive. The remaining controls (seven synovial sarcomas, five desmoid-type fibromatoses, five leiomyomas, five leiomyosarcomas, five Ewing sarcomas, two Wilms' tumors, and two plexiform fibromyxomas) were negative. Review of expression data from 369 gastric carcinomas in The Cancer Genome Atlas (TCGA) 12 revealed two cases (o 1%) with overexpression of GLI1. This affirms that GLI1 IHC may be a useful screen for gastroblastoma.
Gene Expression Profiling
Gene expression profiling was successfully performed in formalin-fixed paraffin-embedded tissue from two of three gastroblastomas, three desmoidtype fibromatosis, five leiomyomas, two plexiform fibromyxomas, two biphasic synovial sarcomas, two Wilms' tumors, and three Sonic Hedgehog-type medulloblastomas. Unsupervised clustering of the expression data showed the gastroblastomas to cluster together, and to show the greatest similarity to Sonic Hedgehog-type medulloblastomas. Both of these tumor types were distinct from the other studied tumors, including the plexiform fibromyxomas ( Figure 5 ).
Discussion
In 2009, Miettinen et al. 1 described a novel biphasic gastric neoplasm of young adults, termed 'gastroblastoma'. The morphological features of these tumors varied little from case to case, and were essentially identical to those of the tumors in the present series. Although little has been previously known about the molecular genetic pathogenesis of gastroblastoma, the results of our study confirm the existence of gastroblastoma as a distinct entity, and show that they represent translocation-associated tumors, characterized by the presence of a somatic, recurrent, oncogenic MALAT1-GLI1 fusion gene.
With the exception of plexiform fibromyxoma (discussed in greater detail below), this fusion gene appears to be specific to gastroblastoma, as we did not identify it in any other studied tumor, and as it has not been previously identified in any of the 369 gastric carcinomas by evaluated by RNASeq and reported in TCGA. 12, 13 It would thus seem that detection of MALAT1-GLI1 fusion gene by D-FISH would be very valuable ancillary test for the confident diagnosis of gastroblastoma. Our data also suggest that immunohistochemistry for GLI1 may be useful for the diagnosis of gastroblastoma, as this protein is consistently expressed in gastroblastoma but not potential morphological mimics. The immunophenotype of gastroblastoma is otherwise nonspecific, typically consisting chiefly of keratin and CD56 expression in the epithelial component, and vimentin, smooth muscle actin, and/ or CD10 expression in the spindled cells.
MALAT1, previously called Alpha, is a long noncoding RNA and is not translated to protein. 14 It is however highly expressed in the nucleus of most cells. 14 Its translocation to GLI1 is expected to drive overexpression of GLI1. Our data confirm this, with GLI1 mRNA and protein overexpression in all studied cases of gastroblastoma. Our data suggest that this overexpressed GLI1 is functional (ie, transcriptionally active), as evidenced by overexpression of several of its known downstream targets with key roles in tumorigenesis-PTCH1, 15-17 SOX2, 18 VEGFA 19 and CCND1. 20 PTCH1 is involved in cell proliferation and organization, 21, 22 SOX2 is a pro-proliferative protein involved in cellular pluripotency, 23, 24 VEGFA is a pro-angiogenic molecule, 25 and CCND1 is involved in the cell cycle. 26 GLI1 is a key protein in the Sonic Hedgehog pathway, 27 and pathway analysis demonstrated upregulation of the Sonic Hedgehog pathway and downregulation of the Sonic Hedgehog antagonistic protein kinase A pathway 27 in our cases of gastroblastoma. The similarity of the gene expression profile of gastroblastoma to Sonic Hedgehog-type medulloblastoma is consistent with these observations. Taken together, these data raise the intriguing possibility that Sonic Hedgehog pathway inhibitors may be effective targeted forms of therapy in patients with locally advanced or metastatic disease.
Both of the MALAT1-GLI1 fusion gene structures in our cases of gastroblastoma include GLI1 exons 6-12 and a novel transcription start site in exon 6. The DNA-binding zinc finger domains of GLI1 are encoded by exons 7-10 and the transactivation domain is encoded by exon 12. As such, the key domains of GLI1 are retained in the novel fusion gene (Supplementary Figure) .
Plexiform fibromyxoma is another recently described, rare gastric tumor that usually occurs in young patients, and is known to harbor the MALAT1-GLI1 fusion gene in a subset of cases. 7 The structure of the MALAT1-GLI1 fusion gene reported in the subset of plexiform fibromyxoma is the same as that seen in gastroblastoma. 7 The fusion gene is believed to have the same functional consequence in both tumor types where it is present. This, of course, raises the question of whether gastroblastoma and plexiform fibromyxoma represent related entities, or even possibly different manifestations of the same entity. However, plexiform fibromyxoma is clinically benign and lacks biphasic morphology, quite different from gastroblastoma. 7, [28] [29] [30] [31] [32] [33] [34] [35] [36] We strongly suspect that the presence of MALAT1-GLI1 fusions in both of these tumors represents simply another example of identical genetic events in unrelated neoplasms, akin to the PAX3-FOXO1 or PAX3-NCOA1 fusions that may be seen in biphenotypic sinonasal sarcomas and alveolar rhabdomyosarcomas, 37, 38 or the EWSR1-ATF1 fusions seen in clear cell sarcoma and angiomatoid fibrous histiocytoma (among others). [39] [40] [41] In conclusion, we have identified a recurrent oncogenic fusion gene in gastroblastoma, MALAT1-GLI1. Despite the extreme rarity of this tumor, the distinctive clinical, morphological, and molecular genetic features of gastroblastoma strongly support its classification as a unique entity. Awareness of this unusual entity, careful morphological study, and ancillary testing for the MALAT1-GLI1 fusion, GLI1 rearrangement, and/or GLI1 protein overexpression should allow for the confident diagnosis of gastroblastoma, and its distinction from various morphological mimics.
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